Cancer Screening, Surrogates of Survival, and the Soma

James DeGregori; Paul Pharoah; Peter Sasieni; Charles Swanton

doi:10.1016/j.ccell.2020.09.003

Cancer Screening, Surrogates of Survival, and the Soma

Cancer Cell. 2020 Oct 12;38(4):433-437. doi: 10.1016/j.ccell.2020.09.003. Epub 2020 Sep 17.

Authors

James DeGregori¹, Paul Pharoah², Peter Sasieni³, Charles Swanton⁴

Affiliations

¹ Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
² Department of Public Health and Primary Care, Department of Oncology, Cambridge Cancer Centre, University of Cambridge, Cambridge, UK.
³ School of Cancer and Pharmaceutical Sciences, King's Clinical Trials Unit, Kings College London, London, UK. Electronic address: peter.sasieni@kcl.ac.uk.
⁴ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Electronic address: charles.swanton@crick.ac.uk.

PMID: 32946774
DOI: 10.1016/j.ccell.2020.09.003

Abstract

Screening leads to meaningful reductions in deaths from cancers. However, reductions in all-cause mortality (ACM) are harder to demonstrate. Failure to demonstrate ACM benefit should not diminish advances in cancer screening. We consider how co-morbidities related to an aging and damaged soma can hinder achievement of ACM benefit.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Aging
Cause of Death
Early Detection of Cancer / methods*
Neoplasms / diagnosis*
Neoplasms / mortality
Neoplasms / therapy*
Risk Assessment
Risk Factors
Smoking
Survival Analysis
Survival Rate

Abstract

Publication types

MeSH terms

Grants and funding